Tirzepatide vs Semaglutide: The Head-to-Head Result, and Its Four Limits

Why does a head-to-head trial matter so much?

Before SURMOUNT-5, comparing these two drugs meant placing the tirzepatide obesity trial next to the semaglutide obesity trial — different populations, different eligibility criteria, different time periods, different protocols. Differences between trial populations routinely produce effect-size gaps as large as the drug differences being investigated.

That makes cross-trial comparison close to uninformative, however confidently it is presented. Randomising the same population to both drugs and following them identically is the only design that supports a superiority claim, and it is why this trial changed the conversation rather than adding to it.

Was one better tolerated?

Both drugs produced gastrointestinal effects in a majority of participants at some point. The meaningful difference was in how often those effects ended treatment: 2.7% discontinued tirzepatide for gastrointestinal reasons against 5.6% for semaglutide.

That combination — more weight reduction and fewer treatment-ending side effects — is unusual. Normally greater efficacy in this class comes with greater gastrointestinal burden. One proposed explanation is that GIP receptor activity, which tirzepatide has and semaglutide does not, may moderate nausea signalling. That remains a hypothesis rather than an established mechanism.

The discontinuation figures are also the numbers most exposed to the open-label design, since deciding to stop involves judgement on both the participant's and the investigator's part.

The four things it does not settle

First, cardiovascular outcomes. SURMOUNT-5 measured weight and waist, not events. Semaglutide carries outcome evidence in specific populations that tirzepatide's programme has not replicated in the same form.

Second, people with type 2 diabetes, who were excluded. Weight response to incretin therapy is consistently smaller when diabetes is present, so this result does not transfer.

Third, individual response. The trial reports group means, and the distribution around them is wide. No available test predicts which drug will suit a given person better.

Fourth, access. Coverage, formulary placement and cash price frequently determine what someone can actually obtain, and none of that was studied.

So which should you take?

If the only consideration were expected weight reduction in a population resembling the trial, the answer would be tirzepatide. But that is rarely the only consideration.

The practical decision usually turns on what your insurance covers, which you tolerate, whether you have a cardiovascular indication where semaglutide's outcome evidence carries weight, and what each costs you specifically. Those are prescriber and plan questions, and they routinely override a difference in trial means.

What does each actually cost you?

Cost rarely tracks efficacy in this category, because pricing is set by channel and coverage rather than by trial results. The same molecule can cost a small copay, a few hundred dollars, or four figures a month depending entirely on what benefit you hold — and that spread is larger than any difference between the two drugs.

Both manufacturers now run direct cash channels that undercut retail substantially, and both operate savings programmes for commercially insured patients with a covered benefit. Neither savings programme is generally available to Medicare or Medicaid beneficiaries, which is the most common source of confusion when someone is quoted a low figure they cannot actually obtain.

The practical sequence is therefore the same regardless of which drug you prefer: establish what your plan covers, find out whether prior authorisation or step therapy applies, and only then compare cash prices as a fallback. Choosing the drug first and discovering the coverage position afterwards is how people end up paying retail.

Frequently asked questions

Sources

• SURMOUNT-5 — New England Journal of Medicine
• SURMOUNT-5 on PubMed
• Trial registration

Every clinical claim above links to a primary source: an FDA record, a peer-reviewed publication with DOI or PMID, or a ClinicalTrials.gov registration. Where a figure could not be verified against a primary source, it is labelled rather than asserted.